{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:55:56Z","timestamp":1789275356610,"version":"build-2803163510"},"reference-count":23,"publisher":"BMJ","issue":"7410","license":[{"start":{"date-parts":[[2003,8,7]],"date-time":"2003-08-07T00:00:00Z","timestamp":1060214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2003,5,23]]},"published-print":{"date-parts":[[2003,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    To determine whether supervised medical prescription of heroin can successfully treat addicts who do not sufficiently benefit from methadone maintenance treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design<\/jats:bold>\n                    Two open label randomised controlled trials.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting<\/jats:bold>\n                    Methadone maintenance programmes in six cities in the Netherlands.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Participants<\/jats:bold>\n                    549 heroin addicts.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Interventions<\/jats:bold>\n                    Inhalable heroin (n = 375) or injectable heroin (n = 174) prescribed over 12 months. Heroin (maximum 1000 mg per day) plus methadone (maximum 150 mg per day) compared with methadone alone (maximum 150 mg per day). Psychosocial treatment was offered throughout.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Main outcome measures<\/jats:bold>\n                    Dichotomous, multidomain response index, including validated indicators of physical health, mental status, and social functioning.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    Adherence was excellent with 12 month outcome data available for 94% of the randomised participants. With intention to treat analysis, 12 month treatment with heroin plus methadone was significantly more effective than treatment with methadone alone in the trial of inhalable heroin (response rate 49.7%\n                    <jats:italic>v<\/jats:italic>\n                    26.9%; difference 22.8%, 95% confidence interval 11.0% to 34.6%) and in the trial of injectable heroin (55.5%\n                    <jats:italic>v<\/jats:italic>\n                    31.2%; difference 24.3%, 9.6% to 39.0%). Discontinuation of the coprescribed heroin resulted in a rapid deterioration in 82% (94\/115) of those who responded to the coprescribed heroin. The incidence of serious adverse events was similar across treatment conditions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    Supervised coprescription of heroin is feasible, more effective, and probably as safe as methadone alone in reducing the many physical, mental, and social problems of treatment resistant heroin addicts.\n                  <\/jats:p>","DOI":"10.1136\/bmj.327.7410.310","type":"journal-article","created":{"date-parts":[[2003,8,7]],"date-time":"2003-08-07T20:15:54Z","timestamp":1060287354000},"page":"310","source":"Crossref","is-referenced-by-count":226,"title":["Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials"],"prefix":"10.1136","volume":"327","author":[{"given":"Wim","family":"van den Brink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent M","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Blanken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten W J","family":"Koeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J","family":"van Zwieten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan M","family":"van Ree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2003,8,7]]},"reference":[{"key":"2025122212151729000_327.7410.310.1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/002204269902900309","article-title":"Medical co-prescription of heroin to chronic, treatment-resistant methadone patients in the Netherlands.","volume":"29","author":"Van den Brink","year":"1999","journal-title":"J Drug Issues"},{"key":"2025122212151729000_327.7410.310.2","unstructured":"Nationale Drug Monitor (NDM) . Jaarbericht NDM 2001. Utrecht: Bureau NDM, 2001."},{"key":"2025122212151729000_327.7410.310.3","unstructured":"Driessen FMHM . Methadonverstrekking in Nederland. Utrecht: Bureau Driessen, 1990."},{"key":"2025122212151729000_327.7410.310.4","unstructured":"Driessen FMHM . Methadoncli\u00ebnten in Nederland. Utrecht: Bureau Driessen, 1992."},{"key":"2025122212151729000_327.7410.310.5","unstructured":"Driessen FMHM V\u00f6lker BGM Kregting J Van der Lelij B . De ontwikkeling van de situatie van methadoncli\u00ebnten gedurende twee jaar. Utrecht: Bureau Driessen, 1999."},{"key":"2025122212151729000_327.7410.310.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06529-1"},{"key":"2025122212151729000_327.7410.310.7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bmj.316.7132.639","article-title":"The Swiss heroin trials: testing alternative approaches.","volume":"316","author":"Farrel","year":"1998","journal-title":"BMJ"},{"key":"2025122212151729000_327.7410.310.8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5694\/j.1326-5377.1998.tb141441.x","article-title":"Prescribing heroin: nothing else to fear but fear itself? Illicit drug policy based on punitive measures has failed, and it is time to seek a health care approach.","volume":"168","author":"Wodak","year":"1998","journal-title":"Med J Austr"},{"key":"2025122212151729000_327.7410.310.9","first-page":"160","article-title":"Report of the external panel on the evaluation of the swiss scientific studies of medically prescribed narcotics to drug addicts.","volume":"45","author":"Ali","year":"1999","journal-title":"Sucht"},{"key":"2025122212151729000_327.7410.310.10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.317.7150.13","article-title":"Randomized trial of heroin maintenance programme for addicts who fail in conventional drug treatments.","volume":"317","author":"Perneger","year":"1998","journal-title":"BMJ"},{"key":"2025122212151729000_327.7410.310.11","unstructured":"American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association, 1994."},{"key":"2025122212151729000_327.7410.310.12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF02029331","article-title":"Analytical studies on illicit heroin. V. Efficacy of volatilization during heroin smoking.","volume":"9","author":"Huizer","year":"1987","journal-title":"Pharmaceutisch Weekblad"},{"key":"2025122212151729000_327.7410.310.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(01)00091-8"},{"key":"2025122212151729000_327.7410.310.14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000259089","article-title":"EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence.","volume":"1","author":"Kokkevi","year":"1995","journal-title":"Eur Addict Res"},{"key":"2025122212151729000_327.7410.310.15","unstructured":"McLellan AT Luborsky L Cacciola J Griffith J McGahan P O'Brien CP . Guide to the addiction severity index: background, administration, and field testing results. Rockville MD: National Institute on Drug Abuse, 1985."},{"key":"2025122212151729000_327.7410.310.16","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800360017003"},{"key":"2025122212151729000_327.7410.310.17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.9312185711.x"},{"key":"2025122212151729000_327.7410.310.18","unstructured":"Derogatis LR . SCL-90-R: administration, scoring and procedures. Manual II. Towsen MD: Clinical Psychometric Research, 1983."},{"key":"2025122212151729000_327.7410.310.19","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.58.2.158"},{"key":"2025122212151729000_327.7410.310.20","doi-asserted-by":"publisher","DOI":"10.1080\/105504901750160448"},{"key":"2025122212151729000_327.7410.310.21","unstructured":"ICH Steering Committee . International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: statistical principles for clinical trials: note for guidance on statistical principles for clinical trials. London: European Agency for Evaluation of Medicinal Products, Human Medicines Evaluation Unit, 1998 (CPMH\/ICG\/33\/95)."},{"key":"2025122212151729000_327.7410.310.22","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1277"},{"key":"2025122212151729000_327.7410.310.23","unstructured":"Rounsaville BJ . Rationale and guidelines for using comparable measures to evaluate substance abusers: an overview. Rounsaville BJ Tims FM Horton AM Sowder BJ eds. Diagnostic source book on drug abuse research and treatment. Rockville, MD: US Department of Health and Human Services, 1993: 1\u201310."}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.327.7410.310","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.327.7410.310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T20:15:22Z","timestamp":1766434522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.327.7410.310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,7]]},"references-count":23,"journal-issue":{"issue":"7410","published-online":{"date-parts":[[2003,8,7]]},"published-print":{"date-parts":[[2003,8,9]]}},"alternative-id":["10.1136\/bmj.327.7410.310"],"URL":"https:\/\/doi.org\/10.1136\/bmj.327.7410.310","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,7]]}}}